High-Volume Hemodiafiltration vs. High-Flux Hemodialysis: Mortality Outcomes at 5 Years
Updated meta-analysis of 7 RCTs confirms survival benefit of HDF in patients achieving adequate convection volumes
Dr. Marcus Chen
Director of Dialysis Services, Columbia University Medical Center
◆ CLINICAL BOTTOM LINE
What was studied
Whether high-volume hemodiafiltration (HDF) reduces all-cause mortality compared to high-flux hemodialysis in maintenance dialysis patients, based on an updated meta-analysis of 7 RCTs (n=4,891).
What was found
High-volume HDF (convection volume ≥23L/session) was associated with a 14% reduction in all-cause mortality (RR 0.86, 95% CI 0.78–0.95) and a 19% reduction in cardiovascular mortality.
What it changes in practice
For dialysis centers with HDF capability, achieving convection volumes ≥23L/session should be a quality target. Patient selection should prioritize those with high cardiovascular risk and residual kidney function.
The debate over hemodiafiltration versus standard hemodialysis has been one of the most contentious in nephrology for over a decade. Early RCTs produced conflicting results, largely because the benefit of HDF appears to be dose-dependent — only patients achieving high convection volumes derive a survival advantage.
An updated meta-analysis now synthesizes data from all 7 completed RCTs, with a total of 4,891 patients and median follow-up of 5 years.
Key Findings
The overall mortality benefit of HDF was modest and not statistically significant when all patients were included (RR 0.93, 95% CI 0.85–1.02). However, in the pre-specified subgroup analysis of patients achieving convection volumes ≥23L/session, the mortality benefit was robust and statistically significant (RR 0.86, 95% CI 0.78–0.95, p=0.002).
Cardiovascular mortality was reduced by 19% in the high-volume HDF group, consistent with the hypothesis that improved clearance of middle molecules (particularly β2-microglobulin and FGF-23) reduces cardiovascular risk.
Barriers to Implementation
High-volume HDF requires high blood flow rates, high-flux membranes, and ultrapure dialysate — infrastructure that is not universally available. Additionally, achieving ≥23L/session requires adequate vascular access, limiting applicability in patients with poor access.
Bottom Line
HDF is not for every patient or every center, but for those with the capability, the mortality data are now sufficiently compelling to justify a quality improvement initiative targeting convection volume adequacy.
Share this with your patient
Generate a plain-language patient handout based on this article's Clinical Bottom Line. Print it, text it, or paste it into your patient portal — in one tap.